anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVES: I. Determine whether methylphenidate decreases fatigue and lethargy in cancer patients receiving interferon alfa. II. Determine whether the use of methylphenidate in this patient population decreases the number of dose reductions of interferon alfa due to toxicities other than myelosuppression or elevated liver function tests. III. Assess whether efficacy or toxicity of methylphenidate in this patient population is concentration dependent. IV. Compare the fatigue subscale and the proposed Brief Fatigue Inventory.

OUTLINE: This is a randomized, double-blind, placebo-controlled, two arm study. Patients are stratified according to initial fatigue level (high vs moderate), and treatment with tumor vaccine (yes vs no). Patients are randomized to one of two treatment arms. Arm I: Patients receive oral methylphenidate twice daily. Arm II: Patients receive oral placebo twice daily. Treatment is continued for 21 consecutive days with dose escalations as tolerated and as needed by patient judgement, followed by an additional week to evaluate the effect of drug withdrawal. Patients are contacted by telephone at least twice weekly during the 21 day treatment and 7 day washout phase to assess adverse or rebound effects. Before the study begins and at weekly clinic visits for the 4 week study period, patients complete a series of questionnaires to measure mood, levels of fatigue and lethargy, and sense of well being. Patients also keep a short daily diary of study medication doses and degree of tiredness. Patients are followed every 3 months for 2 years, then every 6 months for the next 3 years, and then annually thereafter.

PROJECTED ACCRUAL: A total of 200 patients will be accrued into this study within 39 months.
PROBLEM TO BE SOLVED: To obtain the subject medicine capable of preventing and treating cataract, comprising a furanone derivative. SOLUTION: This medicine comprises a furanone derivative of the formula (R1 to R3 are each H, hydroxyl, amino, a halogen, mercapto, carboxyl, carbamoyl, an alkyl, an alkenyl, an aryl, etc.; R4 is H, amino, a halogen, carboxyl, an alkyl, an aryl, an aralkyl, etc.) or its salt as an active ingredient. 2.5-Dimethyl-4-pivaloyloxy-3H(2H)-furanone is preferable as the compound of the formula. A dose is 0.01-1,000mg/time/day/adult in the case of injection. In the case of an internal medicine, the medicine is administered several times per adult daily and a dose is 0.1-1,000mg/time. In the case of an eye drop, one to two drops of 0.01-10% solution are applied once to five times a day drop. Senile cataract based on oxidation disorder can be prevented and treated by instillation or administration.
Use of cotrimoxazole for enterobacterial VAP. Posology and modalities of antibiotic administration will be optimized based on most recent recommendations for ICU patient. They will receive the treatment for 28 days or until death or until ICU discharge if its before 28days.
The invention discloses an Abrin antibody, which comprises a heavy chain and a light chain, wherein the amino acid sequence of the heavy chain variable region is shown as SEQ ID NO. 1 in a sequence table, and the amino acid sequence of the light chain variable region is shown as SEQ ID NO. 2 in the sequence table. Nucleic acid molecules encoding the antibodies are also provided. And the application of the antibody in preparing a medicine for neutralizing Abrin, treating or preventing Abrin poisoning, a cancer targeting medicine and/or an immunotoxin and preparing an Abrin poisoning detection reagent. The antibody provided by the invention can specifically identify Abrin, can obviously inhibit Abrin-a induced cell death in vitro, has a protective effect on cells, can obviously improve the survival rate of mice in vivo, and can prevent 100% of mice from death.
Exposure, Relaxation, and Rescripting Therapy for military populations. 4 sessions.
The invention belongs to the technical field of research and development of medical products. The invention relates to syringa pubescens Turcz. bark extracts with protective effect on alcoholic liver injury. The extracts are prepared by the following steps of: weighing dry coarse powder of syringa pubescens Turcz. barks, soaking the coarse powder in water with weight being 8-10 times that of the coarse powder for 8-10 hours, decocting the solution for 1.5-2 hours, carrying out vacuum filtration after decoction and collecting the filtrate; adding water to decoct the filter residues for 1-1.5 hours, then carrying out ultrasonic processing for 1-1.5 hours under the conditions that the temperature is 30 DEG C and the power is 80W, carrying out vacuum filtration and collecting the filtrate; and mixing the filtrate, concentrating the merged filtrate to extract, drying the extract and grinding the extract, thus obtaining the syringa pubescens Turcz. bark extracts. The extracts are used for preparing the pharmaceutical preparations with protective effect on alcoholic liver injury.
PURPOSE: To provide a local eye lotion compsn. which retains medicines at the eyes for a long time and makes it possible to decrease the number of administration and to make administration at an exact dosage. CONSTITUTION: This local eye lotion compsn. contains carrageenan at a concn. at which the administration as a liquid drop and gel is possible into a vehicle for an eye lotion. This local eye lotion compsn. is shifted from the liquid to the gel by the change in ion intensity and an increase in the concn. of sodium chloride in particular. The method for introducing the medicines into the eyes is executed by locally dosing the compsn. contg. the carrageenan at the concn. at which the administration as the liquid drop and gel is possible at the time of dropping and contg. the medicines and the carrageenan.
A double blind randomized placebo-controlled crossover experimental design with six treatments will be used. A total of 30 young (20-40 year old) healthy men and women will serve as subjects. Following 2 days of physical activity and dietary control, subjects will consume a standard OGTT load or high fat tolerance load on the morning of Day 3. The solution used in the meals will be mixed with one or two servings of non-fat milk or placebo (either carbohydrate matched or total calorie matched). Before and after the test meals are consumed, blood samples will be obtained for later analysis of glucose, triglycerides, insulin, and inflammatory cytokines and brachial artery flow-mediated dilation and femoral artery vascular conductance will be measured. The present research project should provide new and clinically useful insight into the role of conventional dairy products on metabolic homeostasis. If the working hypotheses are supported, the information could be used as an initial/preliminary basis for recommendations for the consumption of fluid milk in the prevention of metabolic diseases.
Participants with acute viral bronchiolitis will receive 3% nebulized hypertonic saline treatments combined with 3 minutes of chest percussion therapy. This will be administered every 6 hours.
There is provided the polynucleotide sequence of a gene whose expression is modulated by hypoxic conditions. Also provided is a polynucleotide sequence encoding a gene for protein 2-2-83. A pharmaceutical composition for modulating hypoxia and ischemia having an effective amount of a polynucleotide or protein having the nucleic acid sequence according to SEQ. ID NO. 1 and 2 or a functional analog thereof and a pharmaceutically acceptable carrier is also provided. There is provided a method of regulating hypoxic associated pathologies and tumorigenesis by administering an effective amount of a polynucleotide, proteins direct or indirect biologically active product of enzymatic activity of the protein, or inhibitors of direct or indirect biologically active product of enzymatic activity of the protein having a nucleic acid sequence from at least one from the group containing SEQ. ID NO.  1 and 2 and functional analogs thereof and a pharmaceutically acceptable carrier. A method of regulating hypoxic associated pathologies and tumorigenesis by inhibiting the enzymatic activity of the protein encoded by the polynucleotide sequences from at least one from the group containing SEQ  ID NO. 1 and 2 and functional analogs thereof is provided. A hypoxia response regulating is further provided. Neuroprotective and neurotrophic agents comprising a gene product of the polynucleotide sequence of 2-2-83 according to SEQ. ID NO. 1 and 2 and functional analogs thereof is also provided. There is provided a method of diagnosing the presence of a hypoxia associated pathology or tumorigenesis by screening for the reduced expression of the gene encoded by the nucleic acid sequence according to SEQ. ID NO. 1 and 2 and functional analogs thereof.
Novel vaccines against human tumours, comprise irradiated EBV-immortalised autologous human B-cells that have been: (a) transfected with a vector contg. segments of the human mucin gene MUC1; and (b) treated with a glycosylation inhibitor so that they express tumour-associated epitopes. Also claimed is the prodn. of a vaccine as above by isolating B-cells from the peripheral blood of a patient, immortalising the B-cells with EBV (produced from a cell line), transfecting the cells with pRep4MUC1 by electroporation, incubating the cells for 24-48 hr. in a culture medium, contg. 5 mM of a glycosylation inhibitor, and irradiating the cells with at least 10000 rad.
PROBLEM TO BE SOLVED: To obtain a new and safe antitumor agent containing an albumin. SOLUTION: This anitiumor agent contains an albumin or its fragment and optionally a buffer solution (e.g. a tris-HCl buffer solution). An albumin is a soluble protein contained in a cell or body fluid of an animal, and a human albumin or a bovine albumin obtained from human or bovine plasma is used as that albumin. The albumin fragment is a fragment having preferably a molecular weight of <=30,000 and a peptide having an amino acid sequence expressed by the formula. The albumin or the albumin fragment in an amount of 3-10mg is dissolved in 1ml of the buffer solution before using. The agent can be formulated into an injection and administered intravenously, intramuscularly or subcutaneously.
Sham transcranial alternating current stimulation (tACS): The procedure for sham stimulation will be identical, but the actual stimulation will last for 2 minutes instead of 30 minutes. Participants generally report that stimulation is felt most strongly at the beginning of active stimulation, before they adjust to the sensation. Sham stimulation is meant to mimic this progression in terms of tactile salience. Stimulation is delivered for 2 minutes at the beginning of the HABIT reversal task, flanked by 10 second linear envelope ramps. The stimulating electrodes are left on the head until completion of the HABIT task, as is the case in active stimulation. There is no visual or auditory indication to the participant or researcher when the 2-minute sham stimulation period has ended, allowing the sham stimulation condition to feel similar to active stimulation.
2-Carbonylthiazole derivatives represented by general formula (I) or pharmaceutically acceptable salts thereof (wherein Ar?1 and Ar2¿ represent each phenyl optionally having one or two substituents selected from among halogeno, C¿1-5? alkyl, trifluoromethyl, C1-5 alkoxy and hydroxy or thienyl; R?1¿ represents C¿1-5? alkoxy, hydroxy or amino represented by the formula N(R?3)R4¿ (wherein R?3 and R4¿ represent each hydrogen or C¿1-5? alkyl, or R?3 and R4¿ together with the nitrogen atom to which they are bonded may form pyrrolidino, piperidino, morphorino or piperazino optionally having one to four substituents selected from among C¿1-5? alkyl, C1-5 alkoxy and hydroxy); Y?1-Y2¿ represents CH-CO or C=C(R2) (wherein R2 represents hydrogen or C¿1-5? alkyl); and n is an integer of 1 to 4); drugs comprising the derivatives represented by the above general formula (I) or pharmaceutically acceptable salts thereof; and dopamine D4 receptor antagonists containing as the active ingredient the same. These drugs are useful as preventives and remedies for various diseases in which dopamine D4 receptors participate, for example, schizophrenia, cerebrovascular disorders and problematic behaviors accompanying senile dementia without showing any extrapyramidal disorders as the side effect.
OBJECTIVES: To investigate the effect of the L-arginine metabolism on arthritis and inflammation-mediated bone loss.
METHODS: L-arginine was applied to three arthritis models (collagen-induced arthritis, serum-induced arthritis and human TNF transgenic mice). Inflammation was assessed clinically and histologically, while bone changes were quantified by μCT and histomorphometry. In vitro, effects of L-arginine on osteoclast differentiation were analysed by RNA-seq and mass spectrometry (MS). Seahorse, Single Cell ENergetIc metabolism by profilIng Translation inHibition and transmission electron microscopy were used for detecting metabolic changes in osteoclasts. Moreover, arginine-associated metabolites were measured in the serum of rheumatoid arthritis (RA) and pre-RA patients.
RESULTS: L-arginine inhibited arthritis and bone loss in all three models and directly blocked TNFα-induced murine and human osteoclastogenesis. RNA-seq and MS analyses indicated that L-arginine switched glycolysis to oxidative phosphorylation in inflammatory osteoclasts leading to increased ATP production, purine metabolism and elevated inosine and hypoxanthine levels. Adenosine deaminase inhibitors blocking inosine and hypoxanthine production abolished the inhibition of L-arginine on osteoclastogenesis in vitro and in vivo. Altered arginine levels were also found in RA and pre-RA patients.
CONCLUSION: Our study demonstrated that L-arginine ameliorates arthritis and bone erosion through metabolic reprogramming and perturbation of purine metabolism in osteoclasts.
A metal treatment composition including Tin (II) Chloride and processed montmorillonite clay. The addition of Tin (II) Chloride to the composition provides Tin for forming a ceramic-metal layer on the surfaces of the friction pair. Tin (II) Chloride provides Chlorine ions for forming Chloric films for protecting juvenile surfaces which form in the friction zone. The clay is heated and pulverized to produce a powder comprising both particles having crystalline layer structure and salts and oxides. The layered crystalline structure of the clay contains slip planes that transversely shift when tangential pressure from the friction pair is applied thereby lubricating the friction pair. The salts and oxides contribute to the formation of the ceramic-metal layer.
Over 9 million Americans have symptomatic osteoarthritis (OA) of the knee, a chronic disease associated with frequent joint pain, functional limitations, and quadriceps weakness that intrude upon everyday life. At least half of those with OA of the knee are diagnosed with hypertension or high blood pressure (HBP), one of the most prevalent risk factors for cardiovascular disease. Many other individuals with OA of the knee unknowingly have HBP and remain untreated. Our own work and that of others suggest that persons with OA of the knee experience reductions in BP when they participate in a regular regimen of physical activity. Even small decreases in systolic and diastolic BP found with physical activity are clinically significant, e.g., a 2 mm Hg decrease reduces the risk of stroke by 14% - 17%, and the risk of coronary heart disease is reduced by 6% - 9%. Yet, only 15% of persons with OA and 47% with HBP engage in regular physical activity. The purpose of this study is to investigate how the individually delivered, home-based, 6-month modified Staying Active with Arthritis (STAR) intervention, guided by self-efficacy theory and modified to address comorbid HBP, affects lower extremity exercise (flexibility, strengthening, and balance), fitness walking, functional status, BP, quadriceps strength, pain, fatigue, and health-related quality of life (HRQoL) in a convenience sample of 224 adults age 50 years or older with OA of the knee and HBP. Using a randomized controlled, 2-group design, we (1) hypothesize that at the end of the 6-month intervention period and 6 months after the intervention period ends those who receive the modified STAR intervention will be more likely to perform lower extremity exercise, participate in fitness walking, show improvements in objective functional status, and demonstrate reductions in BP than those who receive attention-control. Secondarily, we will (2) evaluate the impact of the modified STAR intervention, compared to attention-control, on subjective functional status, quadriceps strength, pain, fatigue, and HRQoL at both time points; (3) explore the impact of the modified STAR intervention, compared to attention-control, on self-efficacy and outcome expectancy at both time points; (4) explore the relationship between self-efficacy and outcome expectancy; and (5) explore the extent to which self-efficacy and outcome expectancy mediate the relationship between the modified STAR intervention and performance of lower extremity exercise and participation in fitness walking. Data will be analyzed using repeated measures modeling.
Treatment with Bendamustine in combination with Lenalidomide and Dexamethasone will be administered on an outpatient basis. Each treatment cycle will be 28 days dosed according to the Dose Escalation Schema.
Dual-specificity phosphatase 26 (DUSP26) acts as a pivotal player in the transduction of signalling cascades with its dephosphorylating activity. Currently, DUSP26 attracts extensive attention due to its particular function in several pathological conditions. However, whether DUSP26 plays a role in kidney ischaemia-reperfusion (IR) injury is unknown. Aims of the current work were to explore the relevance of DUSP26 in kidney IR damage. DUSP26 levels were found to be decreased in renal tubular epithelial cells following hypoxia-reoxygenation (HR) and kidney samples subjected to IR treatments. DUSP26-overexpressed renal tubular epithelial cells exhibited protection against HR-caused apoptosis and inflammation, while DUSP26-depleted renal tubular epithelial cells were more sensitive to HR damage. Upregulation of DUSP26 in rat kidneys by infecting adenovirus expressing DUSP26 markedly ameliorated kidney injury caused by IR, while also effectively reducing apoptosis and inflammation. The mechanistic studies showed that the activation of transforming growth factor-β-activated kinase 1 (TAK1)-JNK/p38 MAPK, contributing to kidney injury under HR or IR conditions, was restrained by increasing DUSP26 expression. Pharmacological restraint of TAK1 markedly diminished DUSP26-depletion-exacebated effects on JNK/p38 activation and HR injury of renal tubular cells. The work reported a renal-protective function of DUSP26, which protects against IR-related kidney damage via the intervention effects on the TAK1-JNK/p38 axis. The findings laid a foundation for understanding the molecular pathogenesis of kidney IR injury and provide a prospective target for treating this condition.
Interventions are urgently needed to improve the delivery and impact of mental health services for persons with serious mental illnesses (SMI) in prison. Treatments addressing the symptoms of mental illness form a critical component of the continuum of services needed by prisoners with SMI. However, a growing body of literature shows that mental health treatments need to be combined with treatments that directly address criminogenic risk factors (i.e., those factors most closely associated with criminal activities). Despite promising evidence, interventions that address criminogenic risk factors, such as Thinking for a Change (T4C), are not used with prisoners with SMI because of the neurocognitive and social impairments associated with SMI. This study examines the effectiveness of T4C with a modified delivery system designed specifically to address the unique needs of persons with SMI in prison. This small-scale randomized controlled trail (RCT) explores the potential effectiveness of T4C-SMI towards improving impulsivity, criminal attitudes, and interpersonal problem solving (treatment targets) and levels of aggression, and the amount of behavioral infractions and time spent in administrative segregation in prison (outcomes). The study will also examine whether the treatment targets for T4C-SMI mediate the intervention's impact on outcomes.

The long-term goal is to grow the evidence-base for interventions with the capacity to improve prison and community-reentry outcomes for persons with SMI. This study will provide the data needed to implement a rigorous RCT in a future study and supports NIMH's mission to develop innovative interventions in mental health services.
In a 2-year oral mouse carcinogenicity study and a 2-year oral rat carcinogenicity study, no drug-related neoplasms were observed in male mice at oral doses of sarecycline up to 100 mg/kg/day (approximately equal to the MRHD based on AUC comparison) or in female mice at doses up to 60 mg/kg/day (approximately equal to the MRHD based on AUC comparison), or in rats at doses up to 200/100 mg/kg/day (dose reduced from 200 to 100 mg/kg/day due to increased mortality; 8 times the MRHD based on AUC comparison).

Sarecycline was not mutagenic or clastogenic in a series of in vitro and in vivo genotoxicity studies, including a bacteria reverse mutation (Ames) assay, an in vitro chromosomal aberration assay in CHO cells, the L5178Y/TK+/- Mouse Lymphoma Assay, and an in vivo micronucleus assay in rats.

In a fertility and early embryonic development study in rats, sarecycline was administered to both male and female rats at oral doses up to 400 mg/kg/day prior to pairing and through the mating and postmating period. Female fertility was not affected at doses up to 400 mg/kg/day (8 times the MRHD based on AUC comparison). In sperm evaluation, decreased sperm motility, decreased sperm count and concentration, and an increase in percent abnormal sperm occurred at 400 mg/kg/day (8 times the MRHD based on AUC comparison). Male fertility was not affected at doses up to 150 mg/kg/day (4 times the MRHD based on AUC comparison).
The invention relates to the field of biotechnology and medicines, in particular to an antibody coupling medicine targeting EGFR and a preparation method thereof. The antibody coupling drug consists of an antibody, a cytotoxic drug and a linker, wherein the antibody is a cetuximab monoclonal antibody, the cytotoxic drug is tripterine, and the linker is a succinimidyl ester linker. Tripterine is firstly transformed into tripterine succinimide ester, and then reacts with amido bond of cetuximab monoclonal antibody to prepare antibody coupling drug. The conjugate has the synergistic biological functions of cetuximab and tripterine, can target EGFR antigen, and has strong activity of killing tumor cells. Compared with Cetuximab, the affinity, the inhibitive ability and the targeting ability of the antibody are not influenced, and the biological function of the antibody is well reserved. In the evaluation of in vitro activity, compared with CTX and CLS used alone or in combination, Cetuximab-SE-Celastrol with equal concentration has better effect, and shows obvious anti-tumor effect under the synergistic effect of the CTX and the CLS.
Epidural Blood Patch: The patient is positioned in the sitting or lateral positon. Using aseptic technique, 20mL of autologous blood is drawn by a trained practitioner. The epidural placement is performed by a trained practitioner using aseptic technique and the vertebral space accessed is at or immediately below the original neuraxial placement. After entrance into the epidural space is confirmed with loss of resistance technique to either air or saline, 15-20 milliliters of sterile autologous venous blood is injected. After the procedure the patient rests supine for at least 1 hour. Patients are instructed to avoid heavy lifting, abdominal straining, or coughing for at least 48 hours.